Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
This distinction between true value and value traps can challenge even the most skilled investors. Luckily for you, we started StockStory to help you uncover exceptional companies. That said, here are three value stocks with little support and some other investments you should consider instead.
PubMatic (PUBM)
Forward P/S Ratio: 1.8x
Powering billions of daily ad impressions across the open internet, PubMatic (NASDAQ: PUBM) operates a technology platform that helps publishers maximize revenue from their digital advertising inventory while giving advertisers more control and transparency.
Why Should You Dump PUBM?
- Platform has low switching costs as its net revenue retention rate of 96% demonstrates high turnover
- Extended payback periods on sales investments suggest the company’s platform isn’t resonating enough to drive efficient sales conversions
- Free cash flow margin is forecasted to shrink by 9.4 percentage points in the coming year, suggesting the company will consume more capital to keep up with its competitors
PubMatic is trading at $11.59 per share, or 1.8x forward price-to-sales. To fully understand why you should be careful with PUBM, check out our full research report (it’s free).
B&G Foods (BGS)
Forward P/E Ratio: 6.4x
Started as a small grocery store in New York City, B&G Foods (NYSE: BGS) is an American packaged foods company with a diverse portfolio of more than 50 brands.
Why Do We Pass on BGS?
- Annual revenue declines of 5.4% over the last three years indicate problems with its market positioning
- Performance over the past three years was negatively impacted by new share issuances as its earnings per share dropped by 19.4% annually, worse than its revenue
- High net-debt-to-EBITDA ratio of 7× increases the risk of forced asset sales or dilutive financing if operational performance weakens
At $4.05 per share, B&G Foods trades at 6.4x forward P/E. Read our free research report to see why you should think twice about including BGS in your portfolio.
Phibro Animal Health (PAHC)
Forward P/E Ratio: 10.1x
With a portfolio of approximately 800 product lines serving farmers and veterinarians in 90 countries, Phibro Animal Health (NASDAQ: PAHC) develops, manufactures, and markets health products for livestock and companion animals, including antibacterials, vaccines, nutritional supplements, and mineral additives.
Why Does PAHC Give Us Pause?
- Revenue base of $1.5 billion puts it at a disadvantage compared to larger competitors exhibiting economies of scale
- Estimated sales growth of 2.2% for the next 12 months implies demand will slow from its two-year trend
- Poor free cash flow margin of 0.8% for the last five years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends
Phibro Animal Health’s stock price of $31.21 implies a valuation ratio of 10.1x forward P/E. If you’re considering PAHC for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
